NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000004150

Registered date:02/09/2010

The effect of remifentanil on cardiac conduction system in pediatric patients undergoing radiofrequency catheter ablation

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedWolff-Parkinson-White syndrome
Date of first enrollment2009/04/01
Target sample size60
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Remifentanil 0.2 microg/kg/min Remifentanil 0.4 microg/kg/min

Outcome(s)

Primary OutcomeAfter anesthetic induction and catheter insertion, CSACT (calculated sinoatrial conduction time) is measured during first EPS (electrophysiological study). And then, remifentanil is administered at a rate of 0.2 or 0.4 microg/kg/min. Almost 10 minutes after remifentanil administration, second EPS and CSACT measurement is performed.
Secondary OutcomeAs with mentioned above, CSNRT (corrected sinus node recovery time), RR interval, and AH interval are measured before and during remifentanil administration.

Key inclusion & exclusion criteria

Age minimum3years-old
Age maximum16years-old
GenderMale and Female
Include criteria
Exclude criteriaExclusion criteria 1) obesity 2) allergy to the trial or companion drugs 3) previous history of kidney, and/or liver disease. 4) patients with severe heart diseases including cardiomyopathy, valvulopathy, and congenital cardiac diseases 5) patients deemed unsuitable for the study by investigators

Related Information

Contact

public contact
Name
Address Japan
Telephone 073-422-4171
E-mail
Affiliation Japanese Red Cross Society Wakayama Medical Center Department of Anesthesiology
scientific contact
Name Hiroshi Iranami
Address Komatsubara-dori 4-20, Wakayama 640-8558, Japan Japan
Telephone 073-422-4171
E-mail
Affiliation Japanese Red Cross Society Wakayama Medical Center Department of Anesthesiology